UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Hematology Highlights: A Post ASH Review
Event

Rivaroxaban Inferior to Warfarin in Prevention of Recurrent Thrombosis in Antiphospholipid Ab Syndrome & Andexanet and Idarucizumab Safe and Effective at Reversing Anticoagulant Effects of DOACs

By UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review FEATURING Brandon J. McMahon

213 views

March 9, 2020

Comments 0

Making the First Chance Count: Manuel

Feat. A. Ip

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

Feat. A. Ip

Hematology Highlights: A Post ASH Review

New Therapies in AML: Is It Safe to Wait for Genomic Info to Start T…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

E. Wang

367 views

AML Treatment Options: Modulating p53 Pathways, Targeting FLT3 Inhib…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

E. Wang

325 views

Harnessing the Immune System - Immunotherapy for AML, Targeting Anti…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

E. Wang

25 views

Malignancy-Associated Thrombosis: DOACs in Treatment of Cancer-Assoc…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

B. McMahon

785 views

Rivaroxaban Inferior to Warfarin in Prevention of Recurrent Thrombos…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

B. McMahon

213 views

ASH 2019 Updates in Indolent NHL: EZH2 Inhibition & Lenalidomide Com…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

N. Fowler

241 views

ASH 2019 Updates in Aggressive NHL: Liso-cel in R/R DLBCL, CD19 Loss…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

N. Fowler

1.1K views

CAR T-cell for MCL, LOXO-305 Effective in Pretreated B-Cell, Nivo an…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

N. Fowler

258 views

ASH 2019 Myeloma Highlights: Genetic Engineering of T-cells, Dara-VM…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

A. Rosko

21 views

Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Th…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

A. Rosko

226 views

ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Respons…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

A. Rosko

133 views

CLL Therapy in 2020 - Ibrutinib+ Rituximab Provides Superior PFS and…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

R. Bociek

322 views

CLL Highlights from ASH: Chemo Free Therapy Achieves MRD Clearance, …

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

R. Bociek

49 views

Impact of Next Generation Sequencing on MDS, Scoring System & Clonal…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

H. Carraway

19 views

Treatment of 62 y/o Man With Low Risk MDS With Anemia: Data on Lenal…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

H. Carraway

190 views

Emerging Therapies in MDS: Novel Oral HMT May Become Basis of New Ba…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

H. Carraway

222 views

ASH 2019 AML Update: Is It Safe to Wait for Genomic Info to Start Th…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

E. Wang

149 views

ASH 2019 AML Update: Ven-based Therapy Can Provide a Path to AlloSCT…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

E. Wang

77 views

ASH 2019 ALL Update: Reduced-intensity Chemo Shows Encouraging Resul…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

E. Wang

27 views

Current Treatment Algorithm & Disease Complications in ET, PV, Myelo…

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

A. Tefferi

1.4K views

ASH 2019 Update in MPN: Triple Negative ET, Ropeginterferon in PV & …

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

A. Tefferi

36 views